Aratana Therapeutics Inc. (PETX) Stock Price Down 2.8%
Aratana Therapeutics Inc. (NASDAQ:PETX) shares fell 2.8% on Thursday . The stock traded as low as $6.51 and last traded at $6.57, with a volume of 359,517 shares traded. The stock had previously closed at $6.76.
Several research firms have recently weighed in on PETX. Lake Street Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Aratana Therapeutics in a research report on Sunday. Credit Suisse Group AG reissued a “buy” rating on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Wednesday. Jefferies Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $11.66.
The stock’s 50-day moving average price is $6.64 and its 200-day moving average price is $5.29. The company’s market capitalization is $232.23 million.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10. During the same period last year, the firm posted ($0.26) EPS. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. Analysts expect that Aratana Therapeutics Inc. will post ($1.02) earnings per share for the current fiscal year.
In other Aratana Therapeutics news, insider Ernst Heinen sold 15,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $6.72, for a total transaction of $100,800.00. Following the completion of the sale, the insider now directly owns 125,494 shares in the company, valued at $843,319.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Peter Steven St sold 100,000 shares of the company’s stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $6.26, for a total transaction of $626,000.00. Following the sale, the chief executive officer now owns 717,793 shares of the company’s stock, valued at $4,493,384.18. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates boosted its position in Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned approximately 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent SEC filing.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.